Meenal Sinha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meenal Sinha has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Lawrence Fong
Division of Translational Science and Therapeutics, Fred Hutch Cancer Center, University of Washington, Seattle, USA
37 shared publications - Alexander Cheung
University of California San Francisco 2 Division of Hematology/Oncology, Department of Medicine San Francisco, California
36 shared publications - Eric V. Liu
Division of Hematology/Oncology, Department of Medicine, University of California
36 shared publications - Brandon K. Chen
University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
35 shared publications - Daniel M. Kim
Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California
35 shared publications - Eric D. Chow
Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA; Center for Advanced Technology, University of California, San Francisco, CA 94158, USA
35 shared publications
Latest Publications
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 3: Expression of immune checkpoints at baseline (A) A uniform manifold approximation and projection (UMAP) plot of cells from all peripheral blood mononuclear cell (PBMC) samples analyzed with Scaffold using data from cytometry by time of flight (CyTOF). Clusters correspond to canonical immune cells and are represented by distinct colors. (B) Expression of PD-L1, TIM3, and CTLA-4 at baseline and post-treatment timepoint 2 (TP2). Raw count of metal ions detected from CyTOF were asinh-transformed, with a higher value corresponding to a higher expression of immune checkpoint.
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 3: Expression of immune checkpoints at baseline (A) A uniform manifold approximation and projection (UMAP) plot of cells from all peripheral blood mononuclear cell (PBMC) samples analyzed with Scaffold using data from cytometry by time of flight (CyTOF). Clusters correspond to canonical immune cells and are represented by distinct colors. (B) Expression of PD-L1, TIM3, and CTLA-4 at baseline and post-treatment timepoint 2 (TP2). Raw count of metal ions detected from CyTOF were asinh-transformed, with a higher value corresponding to a higher expression of immune checkpoint.
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Characteristics of trial patients
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Characteristics of trial patients
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 3: primer sequences
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 3: primer sequences
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NKG2D, OX40, PD-1, PD-L1, PD-L2, TIGIT and TIM3 when comparing patients who did not receive chemotherapy or steroids with patients that received chemotherapy, steroids, or both at pretreatment TP1. Each box in the heatmap represents a lymphocyte cluster that was labeled according to the nearest landmark node they connect to on the scaffold map and ordered by cell count abundance. The pseudocolor represents clusters that showed a significant difference (q<0.05) in the log2 fold change, with red being significantly higher, while blue being significantly lower in group 2 of the two comparison groups.
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 4: Pre-existing immune condition prior to denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NKG2D, OX40, PD-1, PD-L1, PD-L2, TIGIT and TIM3 when comparing patients who did not receive chemotherapy or steroids with patients that received chemotherapy, steroids, or both at pretreatment TP1. Each box in the heatmap represents a lymphocyte cluster that was labeled according to the nearest landmark node they connect to on the scaffold map and ordered by cell count abundance. The pseudocolor represents clusters that showed a significant difference (q<0.05) in the log2 fold change, with red being significantly higher, while blue being significantly lower in group 2 of the two comparison groups.
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NKG2D, OX40, PD-1, PD-L1, PD-L2, TIGIT and TIM3 when comparing (A) patients that received only chemotherapy or chemotherapy and steroids with patients that did not receive chemotherapy or steroids at pretreatment timepoint 1 (TP1) and post-treatment timepoints 2 and 3 (TP2 and TP3); (B) patients received only steroids with patients that received only chemotherapy or chemotherapy and steroids at TP2 and TP3; (C) patients that received only steroids with patients that did not receive chemotherapy or steroids at TP2 and TP3. Each box in the heatmap represents a lymphocyte cluster that was labeled according to the nearest landmark node they connect to on the scaffold map and ordered by cell count abundance. The pseudocolor represents clusters that showed a significant difference (q<0.05) in the log2 fold change, with red being significantly higher, while blue being significantly lower in group 2 of the two comparison groups.
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NKG2D, OX40, PD-1, PD-L1, PD-L2, TIGIT and TIM3 when comparing (A) patients that received only chemotherapy or chemotherapy and steroids with patients that did not receive chemotherapy or steroids at pretreatment timepoint 1 (TP1) and post-treatment timepoints 2 and 3 (TP2 and TP3); (B) patients received only steroids with patients that received only chemotherapy or chemotherapy and steroids at TP2 and TP3; (C) patients that received only steroids with patients that did not receive chemotherapy or steroids at TP2 and TP3. Each box in the heatmap represents a lymphocyte cluster that was labeled according to the nearest landmark node they connect to on the scaffold map and ordered by cell count abundance. The pseudocolor represents clusters that showed a significant difference (q<0.05) in the log2 fold change, with red being significantly higher, while blue being significantly lower in group 2 of the two comparison groups.
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 2: TREC and RANKL quantitation (A) Standard curves of tRNA were prepared on every reaction plate in triplicate for 100,000 to 12 TREC copies and β-actin. (B) Gene expression of RANKL in circulating immune cells was quantified by qPCR. Fold-change expression of RANKL is relative to TP1. (C) Concentration of soluble RANKL from plasma was quantified at pretreatment TP1 and at TP3. (D) Gene expression of RANKL was compared between concurrent therapy groups. Fold-change expression of RANKL is relative to TP1.
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 2: TREC and RANKL quantitation (A) Standard curves of tRNA were prepared on every reaction plate in triplicate for 100,000 to 12 TREC copies and β-actin. (B) Gene expression of RANKL in circulating immune cells was quantified by qPCR. Fold-change expression of RANKL is relative to TP1. (C) Concentration of soluble RANKL from plasma was quantified at pretreatment TP1 and at TP3. (D) Gene expression of RANKL was compared between concurrent therapy groups. Fold-change expression of RANKL is relative to TP1.
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Table 2 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
- Open Access
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NKG2D, OX40, PD-1, PD-L1, PD-L2, TIGIT and TIM3 when comparing (A) patients that received only chemotherapy or chemotherapy and steroids with patients that did not receive chemotherapy or steroids at pretreatment timepoint 1 (TP1) and post-treatment timepoints 2 and 3 (TP2 and TP3); (B) patients received only steroids with patients that received only chemotherapy or chemotherapy and steroids at TP2 and TP3; (C) patients that received only steroids with patients that did not receive chemotherapy or steroids at TP2 and TP3. Each box in the heatmap represents a lymphocyte cluster that was labeled according to the nearest landmark node they connect to on the scaffold map and ordered by cell count abundance. The pseudocolor represents clusters that showed a significant difference (q<0.05) in the log2 fold change, with red being significantly higher, while blue being significantly lower in group 2 of the two comparison groups.
- 4 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Supplementary Figure 5: Effects of concomitant treatments during denosumab treatment Heatmaps summarizing log2 fold changes from statistical analysis of functional markers CD137, CD27, CD40, CD40L, CD71, CD95, CTLA-4, HLA-DR, ICOS, Ki-67, NKG2D, OX40, PD-1, PD-L1, PD-L2, TIGIT and TIM3 when comparing (A) patients that received only chemotherapy or chemotherapy and steroids with patients that did not receive chemotherapy or steroids at pretreatment timepoint 1 (TP1) and post-treatment timepoints 2 and 3 (TP2 and TP3); (B) patients received only steroids with patients that received only chemotherapy or chemotherapy and steroids at TP2 and TP3; (C) patients that received only steroids with patients that did not receive chemotherapy or steroids at TP2 and TP3. Each box in the heatmap represents a lymphocyte cluster that was labeled according to the nearest landmark node they connect to on the scaffold map and ordered by cell count abundance. The pseudocolor represents clusters that showed a significant difference (q<0.05) in the log2 fold change, with red being significantly higher, while blue being significantly lower in group 2 of the two comparison groups.